Retrieved 19 March 2021. Senate of Australia; Community Affairs References Committee (2013). Involuntary or coerced sterilisation of intersex people in Australia. Canberra. ISBN 978-1-74229-917-4. Tamar-Mattis, Anne (2014). "Medical Treatment of People with Intersex Conditions as Torture and Cruel, Inhuman, or Degrading Treatment or Punishment". In Center for Human Rights & Humanitarian Law; Washington College of Law (eds.). Torture in Healthcare Settings: Reflections on the Special Rapporteur on Tortures 2013 Thematic Report. Washington, DC. pp. 91–104. United Nations Office of the High Commissioner for Human Rights (2015). "Free & Equal Campaign Fact Sheet: Intersex" (PDF). UN Committee against Torture; UN Committee on the Rights of the Child; UN Committee on the Rights of People with Disabilities; UN Subcommittee on Prevention of Torture and other Cruel, Inhuman or Degrading Treatment or Punishment; Juan Méndez; Dainius Pῡras; Dubravka Šimonoviæ; Marta Santos Pais; African Commission on Human and Peoples Rights; Council of Europe Commissioner for Human Rights; Inter-American Commission on Human Rights (24 October 2016), "Intersex Awareness Day – Wednesday 26 October. End violence and harmful medical practices on intersex children and adults, UN and regional experts urge", Office of the High Commissioner for Human Rights
World Health Organization; OHCHR; UN Women; UNAIDS; UNDP; UNFPA; UNICEF (2014). Eliminating forced, coercive and otherwise involuntary sterilization, An interagency statement (PDF). ISBN 978-92-4-150732-5. Zwischengeschlecht (March 2014). "IGM – Historical Overview. Hermaphrodites in the Developed World: From Legal Self-Determination to IGM, Supplement 1" (PDF).
The only other treatment approved for LEMS (Firdapse) is only approved for use in adults. Medical uses
Amifampridine is used to treat many of the congenital myasthenic syndromes, particularly those with defects in choline acetyltransferase, downstream kinase 7, and those where any kind of defect causes "fast channel" behaviour of the acetylcholine receptor. It is also used to treat symptoms of Lambert–Eaton myasthenic syndrome. Contraindications
Because it affects voltage-gated ion channels in the heart, it is contraindicated in people with long QT syndrome and in people taking a drug that might prolong QT time like sultopride, disopyramide, cisapride, domperidone, rifampicin or ketoconazol. It is also contraindicated in people with epilepsy or badly controlled asthma. Adverse effects
The dose-limiting side effects include tingling or numbness, difficulty sleeping, fatigue, and loss of muscle strength.Amifampridine can cause seizures, especially but not exclusively when given at high doses and/or in particularly vulnerable individuals who have a history of seizures. Interactions
The combination of amifampridine with pharmaceuticals that prolong QT time increases the risk of ventricular tachycardia, especially torsade de pointes; and combination with drugs that lower the seizure threshold increases the risk of seizures. Interactions via the livers cytochrome P450 enzyme system are considered unlikely. Pharmacology
Mechanism of action
In Lambert–Eaton myasthenic syndrome, acetylcholine release is inhibited as antibodies involved in the host response against certain cancers cross-react with Ca2+ channels on the prejunctional membrane. Amifampridine works by blocking potassium channel efflux in nerve terminals so that action potential duration is increased.